Computational Biologist, Immune Cell Repolarization

Biohub is the first large-scale initiative bringing frontier AI models, massive compute, and frontier experimental capabilities under one roof. We're building a general-purpose system to accelerate scientific discovery, integrating frontier AI models, biological foundation models, and lab capabilities, with the ultimate goal of curing disease. Our technology powers scientists around the world, translating AI capabilities into tools that accelerate research everywhere.

The Team Our immune cell reprogramming team integrates foundational research on immunology and disease biology with AI-modeling to develop engineered cells that harness our own immune system to detect and treat early signs of age-related diseases, like cancer, Alzheimer’s, and Parkinson’s. These technologies will enable precise, context-dependent therapeutic responses only when and where it is needed. You can learn more about our work here . Our work brings together three powerhouse universities - Columbia University, The Rockefeller University, and Yale University - into a single collaborative technology and discovery engine.

Our Vision Pursue large scientific challenges that cannot be pursued in conventional environments Enable individual investigators to pursue their riskiest and most innovative ideas Facilitate research by scientists and clinicians at our home institutions and beyond We are a team of passionate individuals powered by technology, guided by scientific research, and driven by collaboration, working toward a mission to cure or prevent all disease.

The Opportunity

Biohub NY is seeking an accomplished computational biologist experienced in machine learning and transcriptomic data analyses to join our interdisciplinary team. Within the Biohub NY “Immune Cell Re-Programming” group, this role requires experience in research settings, a background in biology, and a proven ability to design, evaluate, and publish innovative computational methodologies that leverage machine learning, statistics, and multi-omics to advance biological research and discovery. Research projects to accelerate the rate of scientific discovery will be assigned by the group leader, Dr. Aleksandar Obradovic, and in collaboration with research teams across the organization. Dr.

Obradovic’s group focuses on leveraging novel approaches for analysis of transcriptional, TCR-Seq, and spatial data across clinical and pre-clinical data toward improved understanding of the immune mechanisms of resistance to checkpoint-inhibitor immunotherapies, with projects aimed at inferring and prioritizing synergistic combination-therapies and regulatory targets for re-programming immune micro-environment (T-cells, macrophages, fibroblasts) toward an anti-tumor phenotype. The ideal candidate will have a strong track record of accomplishments and a dedication to collaborative work within a highly interdisciplinary environment. Please submit a cover letter with your resume.

What You'll Do

Contribute to a dynamic…

Read the full posting